Results 151 to 160 of about 53,113 (297)
DEN Open, Volume 6, Issue 1, April 2026.Abstract While hepatocellular carcinoma (HCC) often invades the portal or hepatic vein to form tumor thrombus, tumor thrombus in the bile duct is rare. In such cases, differentiation from intrahepatic cholangiocarcinoma is difficult, and the tumor often appears as a smooth, yellowish‐white, polypoid mass within the bile duct lumen.
Keisuke Kinoshita +9 more
wiley +1 more source
Atezolizumab in lung cancer—appreciating the differences
, 2016 Stephen V. Liu, Giuseppe Giaccone
openalex +1 more source
International Journal of Cancer, Volume 158, Issue 6, Page 1690-1702, 15 March 2026.What's new? The current standard of care for locally advanced or metastatic renal cell carcinoma (aRCC) is either a combination of two immune checkpoint inhibitors (CPI) or a CPI plus a tyrosine kinase inhibitor (TKI). Here, the authors simulate a head‐to‐head trial comparing the real‐world effectiveness of these combination therapies with TKI ...
Peter J. Goebell +15 more
wiley +1 more source
The role of cytokines in ovarian cancer drug resistance
International Journal of Cancer, Volume 158, Issue 4, Page 821-834, 15 February 2026.Abstract Ovarian cancer is the leading cause of death among women diagnosed with female reproductive system cancers. While significant advances have been made in treating various types of cancer, progress in ovarian cancer treatment over the past 20 years has been minimal, and the treatment course of ovarian cancer is not linear. Although many patients
Lu Wang +7 more
wiley +1 more source
Potential Targets and Biomarkers of Radionuclide Therapy in Breast Cancer
Cancer Innovation, Volume 5, Issue 1, February 2026.Potential biomarkers for the development of targeted radionuclide therapy that can be employed in the treatment of breast cancer have been summarised in the review. They include receptor markers of ER, PR and HER2, as well as other markers of Trop2, PD‐1, EGFR, GRPR and PSMA.
Yujing Tan +3 more
wiley +1 more source